Voyager Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(amounts in thousands, except share and per share data)

Three Months Ended · Nine Months Ended
September 30, · September 30,
2026 · 2025 · 2026 · 2025
Collaboration revenue	$	4,014	$	13,365	$	9,772	$	25,038
Operating expenses:
Research and development		24,371		35,866		71,014		98,722
General and administrative		6,065		8,093		21,842		28,228
Total operating expenses		30,436		43,959		92,856		126,950
Operating loss		(26,422)		(30,594)		(83,084)		(101,912)
Other income, net:
Interest income		1,340		2,385		4,780		8,507
Other income		406		400		1,252		1,245
Total other income, net		1,746		2,785		6,032		9,752
Loss before income taxes		(24,676)		(27,809)		(77,052)		(92,160)
Income tax provision		18		83		52		135
Net loss	$	(24,694)	$	(27,892)	$	(77,104)	$	(92,295)
Other comprehensive (loss) income:
Net unrealized (loss) gain on available-for-sale securities		(208)		228		(661)		414
Total other comprehensive (loss) income		(208)		228		(661)		414
Comprehensive loss	$	(24,902)	$	(27,664)	$	(77,765)	$	(91,881)
Net loss per share, basic and diluted	$	(0.40)	$	(0.47)	$	(1.27)	$	(1.57)
Weighted-average common shares outstanding, basic and diluted		61,824,703		58,803,015		60,631,494		58,608,075

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.